CC-90001 是口服有效的 c-Jun N 末端激酶选择性抑制剂。在基于细胞的模型中，CC-90001显示出对JNK1的选择性是JNK2的 12.9 倍。CC-90001在特发性肺纤维化方面有研究价值。

CC-90001 is an orally administered c-Jun N-terminal kinase (JNK) inhibitor with bias for JNK1 over JNK2.

CC-90001 is 12.9-fold more potent for JNK1 inhibition over JNK2 in knockout fibroblasts[1]. CC-90001 blocks LPS-induced c-jun phosphorylation (EC50 = 480 nM)[2].

CC-90001 decreases multiple measures of lung collagen and reduces disease induced increases in α-SMA to nearly baseline levels in a house dust mite model of lung fibrosis[2]. CC-90001 (3 mg/kg b.i.d.) reduces the development of fibrosis which has been confirmed by a 48% reduction in collagen and a 53% reduction in α-smooth muscle actin (α-SMA) in a steatohepatitis model[2].

1403859-14-2

CC-90001

DMSO:125 mg/mL (388.90 mM)
Powder: -20°C for 3 years
In solvent: -80°C for 2 years